389 related articles for article (PubMed ID: 8490911)
41. Individual cutoff levels of carcinoembryonic antigen and CA 242 indicate recurrence of colorectal cancer with high sensitivity.
Engarås B
Dis Colon Rectum; 2003 Mar; 46(3):313-21. PubMed ID: 12626905
[TBL] [Abstract][Full Text] [Related]
42. [Prognostic value of carcinoembryonic antigen, alpha fetoprotein, carbohydrate antigen 125 and carbohydrate antigen 19-9 in gastroenteropancreatic neuroendocrine neoplasms].
Chen L; Zhang Y; Chen M; Chen J
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1002-1008. PubMed ID: 28900990
[TBL] [Abstract][Full Text] [Related]
43. Carcinoembryonic antigen (CEA), alpha-fetoprotein, CA 19.9 and CA 125 in advanced colorectal cancer (ACC).
Tsavaris N; Vonorta K; Tsoutsos H; Kozatsani-Halividi D; Mylonakis N; Papagrigoriou D; Koutsiouba-Kazakou P; Kosmidis P
Int J Biol Markers; 1993; 8(2):88-93. PubMed ID: 7690061
[TBL] [Abstract][Full Text] [Related]
44. Preoperative serum levels of CA 72-4, CEA, CA 19-9, and alpha-fetoprotein in patients with gastric cancer.
Mattar R; Alves de Andrade CR; DiFavero GM; Gama-Rodrigues JJ; Laudanna AA
Rev Hosp Clin Fac Med Sao Paulo; 2002; 57(3):89-92. PubMed ID: 12118264
[TBL] [Abstract][Full Text] [Related]
45. Clinical study on the serum carcinoembryonic antigen, CA 19-9, CA 50 and alpha-fetoprotein levels in patients with myelodysplastic syndromes.
Dalamaga M; Karmaniolas K; Kontos F; Migdalis I; Dionyssiou-Asteriou A
Leuk Lymphoma; 2006 Sep; 47(9):1782-7. PubMed ID: 17064988
[TBL] [Abstract][Full Text] [Related]
46. A prospective study of the value of imaging, serum markers and their combination in the diagnosis of pancreatic carcinoma in symptomatic patients.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Anticancer Res; 1992; 12(6B):2309-14. PubMed ID: 1295478
[TBL] [Abstract][Full Text] [Related]
47. A novel method for monitoring high-risk breast cancer with tumor markers: CA 15.3 compared to CEA and TPA.
Sölétormos G; Nielsen D; Schiøler V; Skovsgaard T; Winkel P; Mouridsen HT; Dombernowsky P
Ann Oncol; 1993 Dec; 4(10):861-9. PubMed ID: 8117606
[TBL] [Abstract][Full Text] [Related]
48. CEA, CA 242, CA 19-9, CA 72-4 and hCGbeta in the diagnosis of recurrent colorectal cancer.
Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Järvinen H; Haglund C
Tumour Biol; 2004; 25(5-6):228-34. PubMed ID: 15627885
[TBL] [Abstract][Full Text] [Related]
49. Mucin-like cancer-associated antigen (MCA) compared with CA 15-3 in advanced breast cancer.
Steger GG; Mader R; Derfler K; Moser K; Dittrich C
Klin Wochenschr; 1989 Aug; 67(16):813-7. PubMed ID: 2796251
[TBL] [Abstract][Full Text] [Related]
50. Clinical evaluation of potential usefulness of CEA, CA 15-3, and MCA in follow-up of breast cancer patients.
Jezersek B; Cervek J; Rudolf Z; Novaković S
Cancer Lett; 1996 Dec; 110(1-2):137-44. PubMed ID: 9018092
[TBL] [Abstract][Full Text] [Related]
51. Tumor markers for diagnosis, monitoring of recurrence and prognosis in patients with upper gastrointestinal tract cancer.
Jing JX; Wang Y; Xu XQ; Sun T; Tian BG; Du LL; Zhao XW; Han CZ
Asian Pac J Cancer Prev; 2014; 15(23):10267-72. PubMed ID: 25556459
[TBL] [Abstract][Full Text] [Related]
52. Carbohydrate antigens as potential biomarkers for the malignancy in patients with idiopathic deep venous thrombosis: a retrospective cohort study.
Yu M; Wang YH; Abdalla AME; Liu WQ; Mei F; Wang J; Ouyang CX; Li YQ
J Huazhong Univ Sci Technolog Med Sci; 2014 Oct; 34(5):722-728. PubMed ID: 25318883
[TBL] [Abstract][Full Text] [Related]
53. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.
Dolscheid-Pommerich RC; Keyver-Paik M; Hecking T; Kuhn W; Hartmann G; Stoffel-Wagner B; Holdenrieder S
Tumour Biol; 2017 Oct; 39(10):1010428317730246. PubMed ID: 29034816
[TBL] [Abstract][Full Text] [Related]
54. Standard serum concentrations and normal fluctuations of CEA, CA 50 and CA 242 during twelve months in men and women aged 60-64 years without malignant disease.
Engarås B; Hafström L; Kewenter J; Nilsson O; Wedel H
Eur J Surg; 1999 Feb; 165(2):110-6. PubMed ID: 10192567
[TBL] [Abstract][Full Text] [Related]
55. Tumor markers in pancreatic cancer: a comparative clinical study between CEA, CA 19-9 and CA 50.
Molina LM; Díez M; Cava MT; Maestro ML; Ortega MD; Mendíz JG; Prego A; De Diego JA; Balibrea JL
Int J Biol Markers; 1990; 5(3):127-32. PubMed ID: 2286776
[TBL] [Abstract][Full Text] [Related]
56. Tumour-associated trypsin inhibitor (TATI) in patients with colorectal cancer: a comparison with CEA, CA 50 and CA 242.
Pasanen P; Eskelinen M; Kulju A; Penttilä I; Janatuinen E; Alhava E
Scand J Clin Lab Invest; 1995 Apr; 55(2):119-24. PubMed ID: 7667604
[TBL] [Abstract][Full Text] [Related]
57. The usefulness of CA15.3, mucin-like carcinoma-associated antigen and carcinoembryonic antigen in determining the clinical course in patients with metastatic breast cancer.
Deprés-Brummer P; Itzhaki M; Bakker PJ; Hoek FJ; Veenhof KH; de Wit R
J Cancer Res Clin Oncol; 1995; 121(7):419-22. PubMed ID: 7635872
[TBL] [Abstract][Full Text] [Related]
58. CA 19-9 and carcinoembryonic antigen in pancreatic cancer diagnosis.
Del Favero G; Fabris C; Plebani M; Panucci A; Piccoli A; Perobelli L; Pedrazzoli S; Baccaglini U; Burlina A; Naccarato R
Cancer; 1986 Apr; 57(8):1576-9. PubMed ID: 3456255
[TBL] [Abstract][Full Text] [Related]
59. Serum and immunohistochemical studies of NCC-ST-439 in breast cancer.
Narita T; Funahashi H; Satoh Y; Imai T; Takagi H
J Surg Oncol; 1993 Sep; 54(1):5-8. PubMed ID: 8377506
[TBL] [Abstract][Full Text] [Related]
60. Serum CA 19-9 and CEA levels as a prognostic factor in pancreatic adenocarcinoma.
Lee KJ; Yi SW; Chung MJ; Park SW; Song SY; Chung JB; Park JY
Yonsei Med J; 2013 May; 54(3):643-9. PubMed ID: 23549809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
